Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02993237
Other study ID # CR108265
Secondary ID TMC114FD2HTX1003
Status Completed
Phase Phase 1
First received
Last updated
Start date January 23, 2017
Est. completion date May 25, 2017

Study information

Verified date May 2019
Source Janssen Research & Development, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to assess the acceptability of swallowing the darunavir/cobicistat (DRV/COBI) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets, using matching placebo tablets, in human immunodeficiency virus (HIV) -1 infected adolescent patients.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date May 25, 2017
Est. primary completion date May 25, 2017
Accepts healthy volunteers No
Gender All
Age group 12 Years to 17 Years
Eligibility Inclusion Criteria:

- Participant must be male or female between 12 to 17 years of age, inclusive

- Participant must have a body weight of at least 40 kilogram (kg)

- Informed consent must be obtained (from participant and/or his/her parent(s)/legal guardian, as applicable) and an age-appropriate Assent Form, as applicable, indicating that the purpose of, and procedures required for, the study are understood and that the participant is willing to participate in the study

- Participant must be able to comply with the protocol requirements, and adhere to prohibitions and restrictions specified in the protocol

- Participant has documented chronic human immunodeficiency virus (HIV) -1 infection, and is aware of his/her HIV-1 diagnosis

- Participant must be on a stable antiretroviral (ARV) regimen for at least 3 months and has documented plasma HIV-1 ribonucleic acid (RNA) less than (<) 50 copies/ milliLitre (mL) within 3 months prior to screening

- Participant must be willing to assess swallowability of the placebo tablets and be able to do so (as demonstrated by the intake of a reference placebo tablet)

Exclusion Criteria:

- Participant has any condition that, in the opinion of the Investigator, would compromise the study or the well-being of the participant, or prevent the participant from meeting or performing study requirements

- Participant has any condition that, in the opinion of the Investigator, could prevent, limit, or confound the protocol-specified assessments

- Participant has any active clinically significant physical or psychological disease or findings during screening that, in the Investigator's opinion, would compromise the participant's safety, ability to swallow (eg, candidiasis), or outcome of the study

- Participant has history of difficulty with oral intake of ARV therapy or other medications

- Participant is taking disallowed concomitant medications or over-the-counter products

- Participant is a family member of an employee or Investigator of the study site or Participant is a family member of an employee of Johnson & Johnson

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
DRV/COBI FDC placebo tablet
Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC
D/C/F/TAF FDC placebo tablets
Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.

Locations

Country Name City State
United States Emory University Atlanta Georgia
United States University of Texas Health Science Center Houston Texas
United States St Jude Children's Research Hospital Memphis Tennessee
United States Phoenix Children's Hospital Phoenix Arizona

Sponsors (1)

Lead Sponsor Collaborator
Janssen Research & Development, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of Acceptability of Swallowing Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus (HIV)-1 Infected Adolescent Patients Swallowability will be assessed based on a 7-point questionnaire indicating how difficult/easy it was to swallow the tablet, ranging from "very difficult" to "very easy". The acceptability proportion is obtained by a dichotomization of the acceptability/swallowability scale, i.e. 'slightly difficult' or worse versus 'neither difficult nor easy' or better. Day 1
Secondary Acceptability of Daily Intake of the FDC Tablets, by HIV-1 Infected Adolescent Participants Acceptability for long term daily use will be assessed based on a 3-point questionnaire, 'not acceptable', 'acceptable', or 'good to take'. Day 1
See also
  Status Clinical Trial Phase
Completed NCT01968551 - Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults Phase 3
Terminated NCT03708289 - Body Composition, Bone Health and Hormonal Status in HIV-1-infected Individuals
Completed NCT02547844 - Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla Phase 4
Terminated NCT01345630 - Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 Phase 3
Completed NCT00807443 - Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1 Phase 2
Terminated NCT01173276 - Intrauterine Insemination In HIV-Discordant Couples N/A
Completed NCT01140139 - Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions Phase 1
Withdrawn NCT00340223 - HLA-B35 Alleles and AIDS N/A
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT02217904 - A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003) Phase 1
Completed NCT00772902 - ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial Phase 4
Completed NCT04006704 - Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets Phase 1
Terminated NCT03060629 - A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa Phase 2
Recruiting NCT00981695 - Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers Phase 1/Phase 2
Completed NCT00982579 - Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers Phase 1
Completed NCT01084343 - Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects Phase 1
Completed NCT00665847 - TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents Phase 2
Completed NCT00098293 - Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine Phase 3
Completed NCT05944848 - A Study of CL-197 Capsules in Healthy Participants Phase 1
Completed NCT00479999 - Phase 1 Safety Study of Two Experimental HIV Vaccines Phase 1